{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:10:24Z","timestamp":1778825424091,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir plus lamivudine (DTG+3TC) is widely used as a two-drug switch regimen for virologically suppressed PWH. We report long-term real-world data on effectiveness, tolerability, immunological recovery and metabolic\/cardiovascular outcomes in a large, multicentre Italian cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective observational analysis of participants in the ODOACRE cohort who switched to DTG+3TC between January 2015 and January 2025 across eight Italian centres. Inclusion criteria were age \u226518, HIV-RNA &amp;lt;50\u2005copies\/mL for \u22656\u2005months at switch, HBsAg negative. Primary outcomes were time to virological failure (VF) and time to treatment discontinuation (TD) for any cause. Kaplan\u2013Meier survival analysis and Cox regression models were used to evaluate predictors. Changes in metabolic and immunological markers were assessed using linear mixed models and linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2535 participants were included. Estimated probabilities of maintaining virological suppression were 99.5% at 48\u2005weeks, 96.1% at 240\u2005weeks and 90.4% at 480\u2005weeks. In multivariate analysis, longer time since HIV diagnosis (per year aHR 1.038) and zenith HIV-RNA &amp;gt;500\u200a000\u2005copies\/mL (aHR 2.205) predicted VF, whereas longer prior virological suppression was protective (per year aHR 0.869). During 9721.6 PYFU we observed 362 TDs (3.72 per 100 PYFU), with probabilities of regimen maintenance of 94.4%, 83.5% and 78.7% at weeks 48, 240 and 480, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our real-world cohort with extended follow-up, DTG+3TC as a switch regimen was associated with durable virological suppression and favourable tolerability. Metabolic findings should be considered descriptive and exploratory, within the limits of an observational, uncontrolled study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag172","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:12:55Z","timestamp":1777637575000},"source":"Crossref","is-referenced-by-count":0,"title":["\u2018Leaving no stones unturned\u2019: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-883X","authenticated-orcid":false,"given":"Arturo","family":"Ciccullo","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Ospedale San Salvatore , L\u2019Aquila ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-9976","authenticated-orcid":false,"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive , Roma ,","place":["Italia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-7847","authenticated-orcid":false,"given":"Adriana","family":"Cervo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena , Modena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Oreni","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive , Roma ,","place":["Italia"]},{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital , Padua ,","place":["Italy"]},{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore , Roma ,","place":["Italia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gasparro","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Menozzi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena , Modena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cesaretti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana , Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bassani","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Civile di Legnano ASST Ovest Milanese , Legnano ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-8346","authenticated-orcid":false,"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive , Roma ,","place":["Italia"]},{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore , Roma ,","place":["Italia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7910-021X","authenticated-orcid":false,"given":"Alberto","family":"Borghetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana , Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-812X","authenticated-orcid":false,"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena , Siena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Civile di Legnano ASST Ovest Milanese , Legnano ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital , Padua ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9407","authenticated-orcid":false,"given":"Spinello","family":"Antinori","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]},{"name":"III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena , Modena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive , Roma ,","place":["Italia"]},{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore , Roma ,","place":["Italia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026051501335542100_dkag172-B1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 Integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"2026051501335542100_dkag172-B2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026051501335542100_dkag172-B3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026051501335542100_dkag172-B4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026051501335542100_dkag172-B5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/v16020259","article-title":"DOLAMA 200: effectiveness and safety of a dual therapy with dolutegravir plus lamivudine in treatment-experienced HIV-1 infected real world participants in Spain","volume":"16","author":"Sequera-Arquelladas","year":"2024","journal-title":"Viruses"},{"key":"2026051501335542100_dkag172-B6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026051501335542100_dkag172-B7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jac\/dkae392","article-title":"Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort","volume":"80","author":"Ciccullo","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026051501335542100_dkag172-B8","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"key":"2026051501335542100_dkag172-B9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/v16040613","article-title":"Risk of cardiovascular events in people with HIV (PWH) treated with integrase strand-transfer inhibitors: the debate is not over; results of the SCOLTA study","volume":"16","author":"Corti","year":"2024","journal-title":"Viruses"},{"key":"2026051501335542100_dkag172-B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029960","article-title":"Cohort profile: the observational cohort for the study of DOlutegravir in antiretroviral combination REgimens (ODOACRE)","volume":"9","author":"Ciccullo","year":"2019","journal-title":"BMJ Open"},{"key":"2026051501335542100_dkag172-B11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/QAD.0000000000004153","article-title":"\u2018With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV","volume":"39","author":"Baldin","year":"2025","journal-title":"AIDS"},{"key":"2026051501335542100_dkag172-B12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients","volume":"54","author":"Baldin","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026051501335542100_dkag172-B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jac\/dkac362","article-title":"Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV","volume":"78","author":"Ciccullo","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026051501335542100_dkag172-B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026051501335542100_dkag172-B15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/cid\/ciaf100","article-title":"Dolutegravir\/lamivudine for maintenance of virological suppression in persons with historical suspected or confirmed resistance to lamivudine: week 48 results of a single-arm, open-label, multicenter, phase IIa clinical trial","volume":"81","author":"De Miguel","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026051501335542100_dkag172-B16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/v16030348","article-title":"HBcAb positivity as a risk factor for missing HIV RNA undetectability after the 3TC+DTG switch","volume":"16","author":"Malagnino","year":"2024","journal-title":"Viruses"},{"key":"2026051501335542100_dkag172-B17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/v14010163","article-title":"Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort","volume":"14","author":"Ciccullo","year":"2022","journal-title":"Viruses"},{"key":"2026051501335542100_dkag172-B18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice","volume":"78","author":"Su\u00e1rez-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026051501335542100_dkag172-B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"2026051501335542100_dkag172-B20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/hiv.12710","article-title":"Discontinuation of dolutegravir, elvitegravir\/cobicistat and raltegravir because of toxicity in a prospective cohort","volume":"20","author":"Llibre","year":"2019","journal-title":"HIV Med"},{"key":"2026051501335542100_dkag172-B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12981-024-00668-7","article-title":"Virologically suppressed switch to dolutegravir\/lamivudine 2-drug regimen versus switch to commonly prescribed 3-drug regimens in the United States","volume":"21","author":"Pierone","year":"2024","journal-title":"AIDS Res Ther"},{"key":"2026051501335542100_dkag172-B22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ccc.2017.03.007","article-title":"Neuropsychiatric aspects of infectious diseases: an update","volume":"33","author":"Munjal","year":"2017","journal-title":"Crit Care Clin"},{"key":"2026051501335542100_dkag172-B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051501335542100_dkag172-B24","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026051501335542100_dkag172-B25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fendo.2018.00514","article-title":"Insulin resistance in HIV-patients: causes and consequences","volume":"9","author":"Pedro","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026051501335542100_dkag172-B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12933-024-02334-8","article-title":"Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001-2018","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026051501335542100_dkag172-B27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026051501335542100_dkag172-B28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/hiv.13211","article-title":"Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV","volume":"23","author":"Han","year":"2022","journal-title":"HIV Med"},{"key":"2026051501335542100_dkag172-B29","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-54","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","volume":"12","author":"Ryan","year":"2025","journal-title":"Lancet HIV"},{"key":"2026051501335542100_dkag172-B30","doi-asserted-by":"publisher","first-page":"04078","DOI":"10.7189\/jogh.14.04078","article-title":"Cardiovascular disease in people living with HIV: a systematic review and meta-analysis","volume":"14","author":"San","year":"2024","journal-title":"J Glob Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag172\/68289678\/dkag172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag172\/68289678\/dkag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:34:03Z","timestamp":1778823243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag172\/8678569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag172","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag172"}}